| |
| Dear OBGYN Reader - |
| |
| The PartoSure Test was recently FDA approved. |
| |
| Accurately assessing the risk of preterm birth is a major diagnostic challenge with significant implications. Clinical evaluation alone is limited in its ability to predict imminent delivery among patients with signs of threatened preterm labor (PTL). |
| |
| Around 85% of patients admitted for threatened PTL do not deliver within 7 days (1). A more accurate assessment to identify those truly at risk is needed. |
| |
| PartoSure is a rapid, qualitative test to aid in your risk assessment of spontaneous preterm birth within 7 days. The test is for pregnant women with signs and symptoms of early preterm labor. PartoSure test benefits include (2): |
| |
| • |
Results in 5 minutes |
| • |
Semen does not interfere with the results |
| • |
Speculum examination is not required |
| • |
External reader or calibration is not required |
|
| |
 |
| |
| References |
| |
| 1. |
Alfirevic, Z., Allen-Coward, H., Vinuesa, F. (2007) Targeted therapy for threatened preterm labor based on sonographic measurement of the cervical length: a randomized controlled trial. Ultrasound Obstet Gynecol. 29, 47–50. |
| 2. |
PartoSure Test Instructions for Use. QIAGEN, 2018. |
|
| |
|
|
| |
| |
